CTIS2024-514476-40-00进行中（未招募）1 期
Randomized, placebo-controlled, double-blind study to evaluate the efficacy of 2LVERU®JUNIOR and 2LVERU® on the treatment of warts.
abo'Life Belgium0 个研究点目标入组 162 人开始时间: 2024年5月14日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 162
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 0 至 64（—）
- 性别
- All
入选标准
- •Patients, male or female, aged 3 years and older, - Patients with common warts (Verruca vulgaris), and/or plantar warts (Verruca plantaris), and/or flat warts (Verruca plana), - Patients (and/or parents if necessary) having the faculties to understand and respect the constraints of the study, - Signature of the Informed Consent Form by the patient (and/or parents if necessary).
排除标准
- •- Patients who have received any curative warts treatment in the previous 2 months prior to the study, - Patients who have received any homeopathic treatment in the previous 2 months prior to the study, - Patients under immunosuppressive treatment, - Patients having received immunotherapy or micro-immunotherapy during the last 6 months, - Patients with known lactose intolerance, - Pregnant or breastfeeding women, - Patients who participated in a clinical study in the previous 2-months period, - Patients (and/or parents of patients if necessary) who are not sufficiently motivated to engage on the total study follow-up period, or likely to travel or to move before the end of the study, - Patients with severe immunodeficiency disease requiring long term treatment or patients under chemotherapy or radiotherapy, - Patients under listed homeopathic or phytotherapy treatment (see protocol), - Patients addicted to or using recreational drugs, - Patient under guardianship and/or curatorship,
研究者
相似试验
进行中（未招募）
不适用
Randomized, placebo-controlled, double-blind study to investigate the efficacy and safety of a 24-week inhalation treatment with glutathione in cystic fibrosis patients - GSH-4EUCTR2005-003870-88-DEMukoviszidose Institut gGmbH i. G.160
招募中
4 期
Randomized, placebo-controlled, double-blind study to evaluate the efficacy of 2LHERP® in patients with recurrent orofacial herpes infections.2024-514358-56-00Labo'Life Belgium140
进行中（未招募）
1 期
Randomized, placebo-controlled, double-blind study to evaluate the efficacy of 2LEBV® and 2LXFS® on asthenia in patients with an EBV infectioEpstein-Barr Virus infectionMedDRA version: 21.0Level: LLTClassification code: 10056907Term: EBV antigen positive Class: 10022891MedDRA version: 21.1Level: LLTClassification code: 10056906Term: EBV antibody positive Class: 10022891MedDRA version: 23.1Level: LLTClassification code: 10014078Term: EBV infection reactivation Class: 10021881MedDRA version: 20.0Level: LLTClassification code: 10014077Term: EBV infection Class: 10021881CTIS2024-514222-24-00abo'Life Belgium88
进行中（未招募）
1 期
Randomized, placebo-controlled, double-blind study to evaluate the efficacy of 2LPAPI® on the clearance of high-risk oncogenic HPV genital infections (PAPION study)MedDRA version: 25.0Level: LLTClassification code: 10086966Term: HPV screening Class: 100000004848MedDRA version: 25.0Level: LLTClassification code: 10086964Term: HPV infection Class: 100000004848MedDRA version: 20.0Level: SOCClassification code: 10038604Term: Reproductive system and breast disorders Class: 20MedDRA version: 20.0Level: SOCClassification code: 10021881Term: Infections and infestations Class: 1Human Papillomavirus infectionCTIS2024-513969-39-00abo'Life Belgium284
进行中（未招募）
1 期
Randomized, placebo-controlled, double-blind study to evaluate the efficacy of 2LHERP® in patients with recurrent orofacial herpes infections.CTIS2024-514358-56-00abo'Life Belgium140